Kymera Therapeutics, Inc.
Clinical trials sponsored by Kymera Therapeutics, Inc., explained in plain language.
-
New asthma pill could offer hope for severe cases
Disease control Recruiting nowThis study tests an experimental daily pill, KT-621, in adults with moderate to severe eosinophilic asthma that is not well controlled by current inhalers. The goal is to see if the drug improves lung function and asthma control compared to a placebo. About 264 participants will …
Phase: PHASE2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 02:36 UTC
-
New oral eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests an oral medication called KT-621 for people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it safely reduces skin redness, itching, and affected body area compared to a placebo. The trial lasts 16 weeks with a follow-up pe…
Phase: PHASE2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New drug KT-579 enters first human safety tests
Knowledge-focused Recruiting nowThis study is the first time the experimental drug KT-579 is given to humans. It aims to check the drug's safety and how the body processes it in 96 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure d…
Phase: PHASE1 • Sponsor: Kymera Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC